Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study
##plugins.themes.themeTen.article.main##
Keywords
covid-19, hypersensitivity pneumonitis, mortality, risk factors, covid pneumonia, hospitalized patients, observational study, steroid treatment
Abstract
.
References
1. Dessie ZG, Zewotir T. Mortality related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021;21:855 doi: 10.1186/s12879-021-06536
2. 15. Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with intersitital lung disease. Am J Respir Crit Care Med. 2020;202(12):1656-1665. doi:10.1164/rccm.202007-2794OC.
3. Lee H, Hayoung C, Yang B, et al. Interstitial lung disease increases the susceptibility and severity of COVID-19. Eur Respir J 2021;58:2004125. doi: 10.1183/13993003.04125-2020.
4. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81. doi: 10.1016/S2213-2600(20)30079-5.
5. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
6. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-Preliminary report. N Engl J Med. 2021; 384: 693-704. doi:10.1056/NEJMoa2021436.
2. 15. Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with intersitital lung disease. Am J Respir Crit Care Med. 2020;202(12):1656-1665. doi:10.1164/rccm.202007-2794OC.
3. Lee H, Hayoung C, Yang B, et al. Interstitial lung disease increases the susceptibility and severity of COVID-19. Eur Respir J 2021;58:2004125. doi: 10.1183/13993003.04125-2020.
4. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81. doi: 10.1016/S2213-2600(20)30079-5.
5. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
6. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-Preliminary report. N Engl J Med. 2021; 384: 693-704. doi:10.1056/NEJMoa2021436.